Navigation Links
Mount Sinai leads global program using stem cells to accelerate cures for Alzheimer's disease
Date:3/27/2013

Sam Gandy, MD, PhD, of the Icahn School of Medicine at Mount Sinai is leading an international team of researchers working to reprogram skin cells into brain cells to gain a better understanding of Alzheimer's disease (AD). As part of the Consortium, Dr. Gandy is collaborating with Scott Noggle, PhD, the NYSCF Charles Evans Senior Research Fellow for Alzheimer's Disease and Director of the New York Stem Cell Foundation (NYSCF)'s laboratory in Manhattan.

Dr. Gandy heads the Stem Cell Research Consortium funded by the Cure Alzheimer's Fund (CAF). The Consortium consists of six institutions that plan to directly investigate, for the first time, brain cells in petri dishes from individual patients who have the common form of AD.

Dr. Gandy is working with Dr. Noggle's team to reprogram skin cells from AD patients into brain cells using stem-cell technology. The research team will obtain and monitor adult AD brain cells, providing not only a way to study the causes of the disease but also a system for discovering potentially effective drugs. The strategy has been nicknamed "the patient-specific disease in a dish" and enables studies on a time scale of minutes or hours, compared with mouse model testing, which routinely requires nine months to one year.

"This approach is one of our best shots at understanding common forms of Alzheimer's. Once defects are identified, we can use these same brain cells to screen for new drugs," said Dr. Gandy, Professor of Neurology and Psychiatry and Director of the Center for Cognitive Health at Mount Sinai. "This breakthrough technology will enable us to identify genetic and biochemical differences underlying the most common form of Alzheimer's disease."

In collaboration with Mary Sano, PhD, Professor of Psychiatry and Director of the Mount Sinai Alzheimer's Disease Research Center (ADRC), Dr. Gandy plans to select carefully characterized patients and healthy participants from the ADRC who will have skin biopsies and will also undergo brain scans to detect the amount of amyloid plaque, the hallmark of AD, present in the brain. Samples will also be collected from a skin cell bank at the National Institutes of Health. The scans will be used to confirm AD, the risk for developing AD, and whether a brain is amyloid-free.

Dr. Noggle will reprogram these skin cells into the various cell types that make up the brain, employing the NYSCF Global Stem Cell Array, a breakthrough automated robotic technology that produces standardized stem cell lines. Results are specific to the patient's genetic makeup, allowing researchers to uncover Alzheimer's-related changes at an individual level and to track changes that might otherwise go undiscovered.

"Having all the cell types together in the same dish enables us to mimic as closely as possible the normal and the diseased adult human brain," said Dr. Gandy. "In these mixed cultures, we will study the roughly three-dozen genes that have been linked to AD to see if any are dysfunctional in such a way as to cause one or more known features of the disease."

To encourage international collaboration in Alzheimer's treatment, consortium researchers will create a stem cell bank that can be accessed globally to accelerate drug screening worldwide. This collaboration is an example of NYSCF's commitment to work with global collaborators to advance research.

"We can, for the first time, test drugs across a large, diverse population of Alzheimer's patients, using only their cells. This stem cell resource will embolden scientific investigations and accelerate bench to beside delivery of new treatments," said Dr. Noggle. "We're incredibly excited to be working with Dr. Gandy and fellow collaborators to find a cure for Alzheimer's disease."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. Intermountain study finds length of DNA strands can predict life expectancy
2. Antibacterial agent used in common soaps found in increasing amounts in freshwater lakes
3. Evidence mounts for role of mutated genes in development of schizophrenia
4. Mount Sinai grad student, 25, named to Forbes 30 Under 30 in Science and Healthcare
5. New book details the biological and cultural diversity of Khawa Karpo, sacred mountain of Tibet
6. MARC travel awards announced for the 2012 ISCB Rocky Mountain Bioinformatics Conference
7. From Mediterranean coasts to Tatra Mountains and beyond: Plant chromosome number variation
8. Mini-pig tale provides massive amount of genomic data for human health
9. Mongolia and the Altai Mountains: Origins of genetic blending between Europeans and Asians
10. Drought in 2001-2002 fueled Rocky Mountain pine beetle outbreak
11. 2001-2002 drought helped propel mountain pine beetle epidemic, says CU study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/20/2016)... Calif. , Jan. 20, 2016  Synaptics ... of human interface solutions, today announced sampling of ... solution for wearables and small screen applications including ... as printers. Supporting round and rectangular shapes, as ... offers excellent performance with moisture on screen, while ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
Breaking Biology Technology: